Diabetic kidney disease
Nephrology · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
The leading cause of end-stage kidney disease. Detect it early with urine albumin:creatinine ratio, slow it with tight glucose and blood-pressure control plus renin–angiotensin blockade and an SGLT2 inhibitor, and watch for non-diabetic causes when the picture is atypical. First action: annual ACR and eGFR in every person with diabetes.
Red flags
- Refer to nephrology for eGFR <30, rapidly declining function, heavy or rising albuminuria (ACR >70), refractory hypertension/hyperkalaemia, or diagnostic uncertainty (atypical features suggesting non-diabetic disease)
- Admit for severe hyperkalaemia or fluid overload
Assessment
Investigations
- Urine ACR (early morning) and eGFR, repeated to confirm
- Urine dip (haematuria suggests alternative diagnosis)
- HbA1c, lipids, BP
- Renal ultrasound; autoimmune/myeloma screen and nephrology referral if atypical
- Fundoscopy for retinopathy
Management
- Optimise glycaemia (individualised HbA1c) and BP (<130/80 with albuminuria)
- Maximally- tolerated ACEi or ARB (not both) for albuminuria
- Add an SGLT2 inhibitor (proven kidney and cardiovascular protection) and consider the non-steroidal MRA finerenone for residual albuminuria
- Statin, smoking cessation, salt restriction and weight management
- Treat CKD complications (anaemia, bone-mineral, acidosis) as eGFR falls
Disposition
Refer to nephrology for eGFR <30, rapidly declining function, heavy or rising albuminuria (ACR >70), refractory hypertension/hyperkalaemia, or diagnostic uncertainty (atypical features suggesting non-diabetic disease).
Complications & pitfalls
- Progression to end-stage kidney disease needing dialysis or transplant, accelerated cardiovascular disease, hyperkalaemia (worsened by RAS blockade), and fluid overload
Exam pearls
- Start an SGLT2 inhibitor in diabetic kidney disease even when glucose is already controlled — its kidney and heart protection is independent of glycaemic effect, and expect (and tolerate) a small initial eGFR dip.
- Monitoring & follow-up: At least annual (more often if advanced) eGFR and ACR; check U&E within 1–2 weeks of starting/up-titrating ACEi/ARB, SGLT2i or finerenone. Monitor potassium and volume. Review cardiovascular risk and glucose-lowering choices as renal function changes.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.